<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
XLO
Xilio Therapeutics
$
()


  • Xilio Therapeutics expects cash to fund operations into Q2 of 2025

    5/14/2024 - 07:37am
  • Xilio Therapeutics reports Q1 EPS (62c) vs (83c) last year

    5/14/2024 - 07:36am
  • Xilio Therapeutics files to sell 17.58M shares of common stock for holders

    4/30/2024 - 17:11pm
  • Fly Insider: Xilio, Aerovate among week’s notable insider trades

    4/8/2024 - 15:18pm
  • Xilio Therapeutics reports Q4 EPS (64c), consensus (64c)

    4/1/2024 - 16:14pm
  • Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal

    3/28/2024 - 07:22am
  • Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301

    3/28/2024 - 07:13am
  • Xilio Therapeutics announces $11.3M private placement equity financing

    3/28/2024 - 07:10am
  • Xilio to get $43.5M upfront in pact with Gilead to develop/commercialize XTX301

    3/28/2024 - 07:10am
  • Xilio Therapeutics sees advances across clinical pipeline, announces XTX30 data

    1/8/2024 - 08:01am
  • Xilio Therapeutics initiates enrollment for Phase 1 combination trial of XTX101

    12/7/2023 - 07:34am
  • Xilio Therapeutics reports Q3 EPS (61c), consensus (81c)

    11/9/2023 - 16:29pm
  • Xilio Therapeutics price target lowered to $6 from $9 at Guggenheim

    11/7/2023 - 09:22am
  • Xilio reports initial monotherapy safety and anti-tumor activity data for XTX202

    11/3/2023 - 12:06pm
  • Xilio Therapeutics promotes Katarina Luptakova to CMO, Scott Coleman to CDO

    9/5/2023 - 08:41am
dynamic_feed Breaking News